171 related articles for article (PubMed ID: 37504084)
21. Novel DNA methylation biomarkers in stool and blood for early detection of colorectal cancer and precancerous lesions.
Shen Y; Wang D; Yuan T; Fang H; Zhu C; Qin J; Xu X; Zhang C; Liu J; Zhang Y; Wen Z; Tang J; Wang Z
Clin Epigenetics; 2023 Feb; 15(1):26. PubMed ID: 36803423
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous multianalyte immunoassay measurement of five serum tumor markers in the detection of colorectal cancer.
Lumachi F; Marino F; Orlando R; Chiara GB; Basso SM
Anticancer Res; 2012 Mar; 32(3):985-8. PubMed ID: 22399621
[TBL] [Abstract][Full Text] [Related]
23. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.
Caglar M; Yener C; Karabulut E
Int J Comput Assist Radiol Surg; 2015 Jul; 10(7):993-1002. PubMed ID: 25213271
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Performance of a Novel Multiplex Immunoassay in Colorectal Cancer.
Dressen K; Hermann N; Manekeller S; Walgenbach-Bruenagel G; Schildberg FA; Hettwer K; Uhlig S; Kalff JC; Hartmann G; Holdenrieder S
Anticancer Res; 2017 May; 37(5):2477-2486. PubMed ID: 28476816
[TBL] [Abstract][Full Text] [Related]
25. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.
Zhang Z; Yu Y; Xu F; Berchuck A; van Haaften-Day C; Havrilesky LJ; de Bruijn HW; van der Zee AG; Woolas RP; Jacobs IJ; Skates S; Chan DW; Bast RC
Gynecol Oncol; 2007 Dec; 107(3):526-31. PubMed ID: 17920110
[TBL] [Abstract][Full Text] [Related]
26. The utility and prognostic value of CA 19-9 and CEA serum markers in the long-term follow up of patients with colorectal cancer. A single-center experience over 13 years.
Tumay V; Guner OS
Ann Ital Chir; 2020; 91():494-503. PubMed ID: 32990277
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of combining serum tumor marker detection with fecal occult blood testing in diagnosing colorectal cancer.
Zhou H; Wang XC; Yuan BB; Lu BB
J Physiol Pharmacol; 2022 Jun; 73(3):. PubMed ID: 36515627
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis of pancreatic carcinoma based on combined measurement of multiple serum tumor markers using artificial neural network analysis.
Yang Y; Chen H; Wang D; Luo W; Zhu B; Zhang Z
Chin Med J (Engl); 2014; 127(10):1891-6. PubMed ID: 24824251
[TBL] [Abstract][Full Text] [Related]
29. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
[TBL] [Abstract][Full Text] [Related]
30. [The optimal combination of serum tumor markers with bioinformatics in diagnosis of colorectal carcinoma].
Yu JK; Yang MQ; Jiang TJ; Zheng S
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2004 Sep; 33(5):407-10. PubMed ID: 15476323
[TBL] [Abstract][Full Text] [Related]
31. [Application of serum protein pattern model in diagnosis of colorectal cancer].
Chen YD; Zheng S; Yu JK; Hu X
Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):417-20. PubMed ID: 15355647
[TBL] [Abstract][Full Text] [Related]
32. Improved diagnosis of colorectal cancer using combined biomarkers including Fusobacterium nucleatum, fecal occult blood, transferrin, CEA, CA19-9, gender, and age.
Zhao R; Xia D; Chen Y; Kai Z; Ruan F; Xia C; Gong J; Wu J; Wang X
Cancer Med; 2023 Jul; 12(13):14636-14645. PubMed ID: 37162269
[TBL] [Abstract][Full Text] [Related]
33. Identifying potential DNA methylation markers in early-stage colorectal Cancer.
Zhang X; Wan S; Yu Y; Ruan W; Wang H; Xu L; Wang C; Chen S; Cao T; Peng Q; Li S; Hu T; Jiang Z; Chen Z; Fan JB
Genomics; 2020 Sep; 112(5):3365-3373. PubMed ID: 32531444
[TBL] [Abstract][Full Text] [Related]
34. The Importance of Determining Preoperative Serum Concentration of Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen in Assessing the Progression of Colorectal Cancer.
Halilovic E; Rasic I; Sofic A; Mujic A; Rovcanin A; Hodzic E; Kulovic E
Med Arch; 2020 Oct; 74(5):346-349. PubMed ID: 33424087
[TBL] [Abstract][Full Text] [Related]
35. Improved risk scoring systems for colorectal cancer screening in Shanghai, China.
Wu WM; Gu K; Yang YH; Bao PP; Gong YM; Shi Y; Xu WH; Fu C
Cancer Med; 2022 May; 11(9):1972-1983. PubMed ID: 35274820
[TBL] [Abstract][Full Text] [Related]
36. Applications of Artificial Intelligence in Screening, Diagnosis, Treatment, and Prognosis of Colorectal Cancer.
Qiu H; Ding S; Liu J; Wang L; Wang X
Curr Oncol; 2022 Mar; 29(3):1773-1795. PubMed ID: 35323346
[TBL] [Abstract][Full Text] [Related]
37. Correlation between Stool DNA-based SDC2 Methylation Tests Combined with Tumor Markers with Pathological Features in Colorectal Cancer.
Cheng Z; Wang Y; Wei W; Liu Y; Zhou Z
Clin Lab; 2023 Jul; 69(7):. PubMed ID: 37436377
[TBL] [Abstract][Full Text] [Related]
38. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
[TBL] [Abstract][Full Text] [Related]
39. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions.
Tänzer M; Balluff B; Distler J; Hale K; Leodolter A; Röcken C; Molnar B; Schmid R; Lofton-Day C; Schuster T; Ebert MP
PLoS One; 2010 Feb; 5(2):e9061. PubMed ID: 20140221
[TBL] [Abstract][Full Text] [Related]
40. The application of artificial intelligence in improving colonoscopic adenoma detection rate: Where are we and where are we going.
Gan P; Li P; Xia H; Zhou X; Tang X
Gastroenterol Hepatol; 2023 Mar; 46(3):203-213. PubMed ID: 35489584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]